Hims & Hers Health, Inc. $HIMS Shares Sold by AlphaQuest LLC

AlphaQuest LLC decreased its position in Hims & Hers Health, Inc. (NYSE:HIMS) by 10.7% in the 1st quarter, Holdings Channel reports. The fund owned 3,467 shares of the company’s stock after selling 415 shares during the period. AlphaQuest LLC’s holdings in Hims & Hers Health were worth $102,000 as of its most recent SEC filing.

Several other large investors also recently bought and sold shares of HIMS. Farallon Capital Management LLC grew its position in Hims & Hers Health by 64,338.5% in the fourth quarter. Farallon Capital Management LLC now owns 8,377,000 shares of the company’s stock valued at $202,556,000 after acquiring an additional 8,364,000 shares in the last quarter. Nuveen LLC acquired a new stake in Hims & Hers Health in the first quarter valued at approximately $58,403,000. Yong Rong HK Asset Management Ltd grew its position in Hims & Hers Health by 41.2% in the first quarter. Yong Rong HK Asset Management Ltd now owns 2,400,000 shares of the company’s stock valued at $70,920,000 after acquiring an additional 700,100 shares in the last quarter. CloudAlpha Capital Management Limited Hong Kong acquired a new stake in Hims & Hers Health in the first quarter valued at approximately $20,580,000. Finally, Two Sigma Investments LP grew its position in Hims & Hers Health by 37.9% in the fourth quarter. Two Sigma Investments LP now owns 1,967,354 shares of the company’s stock valued at $47,571,000 after acquiring an additional 540,274 shares in the last quarter. Institutional investors and hedge funds own 63.52% of the company’s stock.

Hims & Hers Health Stock Performance

Shares of HIMS opened at $41.63 on Wednesday. The business’s fifty day moving average price is $49.95 and its 200 day moving average price is $45.57. Hims & Hers Health, Inc. has a 12-month low of $13.47 and a 12-month high of $72.98. The stock has a market capitalization of $9.41 billion, a PE ratio of 52.03, a price-to-earnings-growth ratio of 2.86 and a beta of 2.14. The company has a debt-to-equity ratio of 1.72, a current ratio of 4.98 and a quick ratio of 4.46.

Hims & Hers Health (NYSE:HIMS) last announced its quarterly earnings data on Monday, August 4th. The company reported $0.17 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.18 by ($0.01). Hims & Hers Health had a return on equity of 26.26% and a net margin of 9.63%.The firm had revenue of $544.83 million for the quarter, compared to the consensus estimate of $550.06 million. During the same quarter last year, the business earned $0.06 earnings per share. The business’s revenue for the quarter was up 72.6% compared to the same quarter last year. Hims & Hers Health has set its Q3 2025 guidance at EPS. FY 2025 guidance at EPS. Equities research analysts forecast that Hims & Hers Health, Inc. will post 0.29 EPS for the current year.

Analysts Set New Price Targets

Several analysts have issued reports on HIMS shares. Citigroup reaffirmed a “sell” rating on shares of Hims & Hers Health in a research report on Monday, June 23rd. Needham & Company LLC reaffirmed a “hold” rating on shares of Hims & Hers Health in a research report on Tuesday, August 5th. Piper Sandler reissued a “neutral” rating and set a $39.00 price target (up previously from $35.00) on shares of Hims & Hers Health in a research report on Tuesday, May 6th. Morgan Stanley reissued an “equal weight” rating and set a $40.00 price target on shares of Hims & Hers Health in a research report on Wednesday, June 11th. Finally, Deutsche Bank Aktiengesellschaft reissued a “hold” rating on shares of Hims & Hers Health in a research report on Wednesday, May 7th. Two investment analysts have rated the stock with a Buy rating, eight have given a Hold rating and three have issued a Sell rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Reduce” and a consensus target price of $38.92.

Insider Transactions at Hims & Hers Health

In related news, insider Michael Chi sold 17,102 shares of the firm’s stock in a transaction on Tuesday, June 17th. The stock was sold at an average price of $59.75, for a total transaction of $1,021,844.50. Following the transaction, the insider directly owned 278,654 shares in the company, valued at $16,649,576.50. This trade represents a 5.78% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CFO Oluyemi Okupe sold 23,107 shares of the firm’s stock in a transaction on Monday, June 23rd. The stock was sold at an average price of $47.25, for a total value of $1,091,805.75. Following the transaction, the chief financial officer owned 63,222 shares in the company, valued at $2,987,239.50. This trade represents a 26.77% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 1,395,428 shares of company stock valued at $71,753,898. Company insiders own 17.71% of the company’s stock.

About Hims & Hers Health

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.